Internal Medicine, Gastroenterology · Fresno, CA
NPI
1205924800
Since 2006
Specialty
Internal Medicine, Gastroenterology
Code 207RG0100X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
1187 E Herndon Ave, #101
Fresno, CA, 93720
Phone (559) 440-0450
Groups this clinician bills Medicare through
Medicare paid, 2024
$119K
1,140 services
Medicare patients, 2024
596
Average age 73
Drug cost, 2024
$776K
1,132 prescriptions
Company payments, 2025
$1,067
From 12 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Soo Y Kim was code 99214 (office e&m - established), 272 times for 211 patients. In total Soo Y Kim billed 1,140 services in 30 codes, and Medicare paid $119K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-05-23.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 272 | 211 | $97.19 | $26K |
| 99213 Office E&M - Established | Office | 229 | 194 | $63.70 | $15K |
| 45380 Lower GI Endoscopy - Other | Facility | 198 | 196 | $101.70 | $20K |
| 43239 Upper GI Endoscopy | Facility | 121 | 114 | $86.82 | $11K |
| 45385 Colonoscopy - Lesion Removal | Facility | 116 | 115 | $205.01 | $24K |
| G0105 Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 42 | 42 | $177.24 | $7,444 |
| 99204 Office E&M - New | Office | 26 | 26 | $124.72 | $3,243 |
| 45378 Lower GI Endoscopy - Other | Facility | 16 | 16 | $124.03 | $1,984 |
| G0121 Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 13 | 13 | $166.02 | $2,158 |
| 43450 Digestive/Gastrointestinal | Facility | 12 | 12 | $32.16 | $386 |
| 99222 Hospital E&M - Initial | Facility | 11 | 11 | $102.83 | $1,131 |
By year: 2022 $118K for 1,231 services; 2023 $122K for 1,214 services; 2024 $119K for 1,140 services.
Medicare prescription drug claims, 2024
In 2024, the drug Soo Y Kim prescribed most often to Medicare patients was Omeprazole, with 217 prescriptions and refills. In total Soo Y Kim wrote 1,132 Medicare prescriptions that cost $776K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Omeprazole Generic | 217 | 598 | 74 | $2,579 |
| Pantoprazole Sodium Generic | 184 | 521 | 64 | $2,799 |
| Lubiprostone Generic | 75 | 164 | 28 | $23K |
| Linzess Linaclotide | 74 | 129 | 22 | $65K |
| Famotidine Generic | 68 | 190 | 22 | $1,581 |
| Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl | 46 | 46 | 45 | $573 |
| Ursodiol Generic | 39 | 109 | 12 | $13K |
| Amitriptyline Hcl Generic | 39 | 94 | 12 | $458 |
| Dicyclomine Hcl Generic | 33 | 73 | 13 | $983 |
| Motegrity Prucalopride Succinate | 31 | 67 | Under 11 | $44K |
| Esomeprazole Magnesium Generic | 22 | 63 | Under 11 | $1,723 |
| Cholestyramine Cholestyramine (With Sugar) | 19 | 27 | Under 11 | $1,793 |
| Mesalamine Generic | 18 | 53 | Under 11 | $17K |
| Lactulose Generic | 17 | 34 | Under 11 | $408 |
| Lansoprazole Generic | 17 | 40 | Under 11 | $5,317 |
Brand drugs: - claims; generic drugs: 888 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Soo Y Kim $1,067 ($1,067 in general payments such as food, travel and fees) from 12 companies. The largest payer was Abbvie Inc. with $357.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 21 | $357 |
| Madrigal Pharmaceuticals MDGL | 4 | $203 |
| Boston Scientific Corporation BSX | 3 | $97.34 |
| Cook Medical LLC | 1 | $96.83 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC BHC | 4 | $91.32 |
| Gilead Sciences, Inc. GILD | 2 | $53.03 |
| Ipsen Biopharmaceuticals, Inc IPN.PA | 2 | $40.12 |
| Phathom Pharmaceuticals, Inc. PHAT | 2 | $32.73 |
| Genzyme Corporation SNY | 1 | $30.07 |
| Janssen Biotech, Inc. JNJ | 1 | $25.05 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.